Sign In

Print this! Bookmark and Share

CVRN Research-Anticoagulation

Community-Based Control and Persistence of Warfarin Therapy and Associated Rates and Predictors of Adverse Clinical Events in Atrial Fibrillation and Venous Thromboembolism

PI: Alan S. Go MD

While the oral vitamin K antagonist, warfarin, is the most commonly prescribed anticoagulant in the U.S. for the prevention and chronic treatment of thromboembolism, we have few insights into the contemporary quality of care and associated outcomes among large, diverse populations within typical care settings. Through the CVRN, we have constructed a multi-center cohort of anticoagulated patients with atrial fibrillation or venous thromboembolism to examine how effectively warfarin therapy is being delivered outside of clinical trial settings, to determine the absolute risks of adverse events associated with warfarin, and to delineate predictors of suffering a warfarin-related adverse outcome.

For more information, check out the WAVE Dataset page.

Contact Information:

Managed by Kaiser Permanente Division of Reseasrch
Content in this Web site is the property of CVRN - Cardiovascular Research Network. All rights reserved, ©